Why the study?
Does the novel cardiotonic agent denopamine have weaker arrhythmogenic activity compared to standard catecholamines in canine models?
Does the novel cardiotonic agent denopamine have weaker arrhythmogenic activity compared to standard catecholamines in canine models?
In canine models, the novel cardiotonic agent denopamine provides positive inotropic effects with significantly weaker arrhythmogenic properties than standard catecholamines like dobutamine and dopamine.
Denopamine may widen the inotrope safety margin in canines; hypothesis-generating and should not yet inform practice.
We studied the arrhythmogenic activity of denopamine, in relation to its positive inotropic action, in dogs and compared it with those of catecholamines. The positive inotropic activities of the compounds as expressed in terms of the ED100 (microgram/kg, i.v.), that increased LV dp/dt max of anesthetized dogs by 100% of the control were 8.0 for denopamine, 0.27 for norepinephrine, 0.03 for isoproterenol, 3.8 for dobutamine and 16 for dopamine. On the other hand, the doses of these drugs at which the "non-sinus/total rate" increased significantly (about 30% of total beats, microgram/kg, i.v.) were more than 1000 for denopamine, 1.0 for norepinephrine and isoproterenol, and 300 for dobutamine and dopamine in coronary ligated dogs. The ratios of these doses to the ED100 are more than 126 for denopamine, 80 for dobutamine, 33 for isoproterenol, 19 for dopamine and 3.8 for norepinephrine. Arrhythmogenic activity of denopamine was also weaker than those of dobutamine and dopamine in halothane anesthetized dogs. The arrhythmogenic activity of dobutamine was weak as reported, but that of denopamine was the weakest among the drugs tested.
No takes yet. Share an insight, caveat, or question.
Narita et al. (1986) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: